Most-cited articles · 2024

The 10 most-cited articles in The Medical Journal of Australia, 2024

Ranked by OpenAlex citation count on 29 October 2026, out of 282 eligible articles The Medical Journal of Australia published in 2024. Ranks are frozen; this page will not change. Number one, with 119 citations: Screening and prevention of ovarian cancer.

Cohort
282 articles
Listed
Top 10 (3.5%)
Open access
10 of 10
Snapshot
2026-10-29

The most-cited articles published in the Medical Journal of Australia in 2024 are led by clinical guidelines and consensus statements, alongside reviews and analyses of disease prevention and public health. The top paper, "Screening and prevention of ovarian cancer" by Sideris, Menon and Manchanda, received 119 citations. Other highly cited works address cardiovascular disease risk assessment, doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections, scabies, hypertension in pregnancy, and patient blood management for critical bleeding.

Readers can use this list to see which 2024 MJA articles attracted the most scholarly attention, as measured by OpenAlex citation counts among 282 eligible articles. The ranking reflects citation activity rather than a judgment of clinical importance, and the topics represented span prevention, guideline development, and health system questions such as artificial intelligence in Australian health care.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.4%

    Screening and prevention of ovarian cancer

    Michail Ch. Sideris, Usha Menon, Ranjit Manchanda

    119 citationsOpen access (CC-BY)doi:10.5694/mja2.52227OpenAlex

    Show abstract

    Ovarian cancer remains the most lethal gynaecological malignancy with 314 000 cases and 207 000 deaths annually worldwide. Ovarian cancer cases and deaths are predicted to increase in Australia by 42% and 55% respectively by 2040. Earlier detection and significant downstaging of ovarian cancer have been demonstrated with multimodal screening in the largest randomised controlled trial of ovarian cancer screening in women at average population risk. However, none of the randomised trials have demonstrated a mortality benefit. Therefore, ovarian cancer screening is not currently recommended in women at average population risk. More frequent surveillance for ovarian cancer every three to four months in women at high risk has shown good performance characteristics and significant downstaging, but there is no available information on a survival benefit. Population testing offers an emerging novel strategy to identify women at high risk who can benefit from ovarian cancer prevention. Novel multicancer early detection biomarker, longitudinal multiple marker strategies, and new biomarkers…

  2. 2
    top 0.8%

    2023 Australian guideline for assessing and managing cardiovascular disease risk

    Mark Raymond Nelson, Emily Banks, Alex D. H. Brown, Clara Kayei Chow, David Peiris and 6 more

    89 citationsOpen access (CC-BY-NC-ND)doi:10.5694/mja2.52280OpenAlex

    Show abstract

    INTRODUCTION: The 2023 Australian guideline for assessing and managing cardiovascular disease risk provides updated evidence-based recommendations for the clinical assessment and management of cardiovascular disease (CVD) risk for primary prevention. It includes the new Australian CVD risk calculator (Aus CVD Risk Calculator), based on an equation developed from a large New Zealand cohort study, customised and recalibrated for the Australian population. The new guideline replaces the 2012 guideline that recommended CVD risk assessment using the Framingham risk equation. MAIN RECOMMENDATIONS: The new guideline recommends CVD risk assessment in people without known CVD: all people aged 45-79 years, people with diabetes from 35 years, and First Nations people from 30 years. The new Aus CVD Risk Calculator should be used to estimate and categorise CVD risk into low (< 5% risk over five years), intermediate (5% to < 10% risk over five years) or high risk (≥ 10% over five years). The following reclassification factors may be applied to recategorise calculated risk to improve accuracy of…

  3. 3
    top 1.1%

    Australian consensus statement on doxycycline post‐exposure prophylaxis ( doxy‐PEP ) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men

    Vincent J. Cornelisse, Benjamin Riley, Nicholas Medland

    69 citationsOpen access (CC-BY-NC-ND)doi:10.5694/mja2.52258OpenAlex

    Show abstract

    INTRODUCTION: Doxycycline post-exposure prophylaxis (doxy-PEP) involves consuming 200 mg of doxycycline up to 72 hours after a condomless sex act to reduce the risk of bacterial sexually transmitted infections (STIs). Recent clinical trials of doxy-PEP have demonstrated significant reductions in syphilis, chlamydia and, to a lesser degree, gonorrhoea among gay, bisexual and other men who have sex with men (GBMSM). There is a high level of interest in doxy-PEP in the GBMSM community and, in response, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) held a national consensus conference with the aim of creating preliminary guidance for clinicians, community, researchers and policy makers. MAIN RECOMMENDATIONS: There was broad agreement that doxy-PEP should be considered primarily for the prevention of syphilis in GBMSM who are at risk of this STI, with a secondary benefit of reductions in other bacterial STIs. At the end of the consensus process, there remained some disagreement, as some stakeholders felt strongly that doxy-PEP should be considered…

  4. 4
    top 1.5%

    Scabies: a clinical update

    Laxmi Iyengar, Alvin H Chong, Andrew C. Steer

    55 citationsOpen accessdoi:10.5694/mja2.52505OpenAlex

    Show abstract

    BACKGROUND: Scabies is a common, yet neglected, skin disease. Scabies occurs across Australia, but most frequently in socioeconomically disadvantaged populations in tropical regions, including in remote Aboriginal and Torres Strait Islander communities. In temperate settings, the disease clusters in institutional care facilities. OBJECTIVE: The objective of this article is to provide updates on the clinical diagnosis and treatment approaches for scabies in Australia. DISCUSSION: Clinical examination remains the mainstay of diagnosis, although dermatoscopy is a useful adjunct. Scabies presents with severe itch and a papular rash, with a predilection for the hands, feet and genitalia. The distribution may be more widespread in infants and older people. Secondary bacterial infection is also common in patients with scabies. Crusted scabies is a rare but highly infectious variant. Topical permethrin is highly effective for individual treatment, but less practical for treatment of asymptomatic contacts and control of outbreaks. Oral ivermectin is a safe and effective alternative, and is…

  5. 5
    top 1.8%

    A summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand ( SOMANZ ) hypertension in pregnancy guideline

    Renuka Shanmugalingam, Helen L. Barrett, Amanda Beech, Lucy Bowyer, Tim M.E. Crozier and 23 more

    48 citationsOpen access (CC-BY-NC-ND)doi:10.5694/mja2.52312OpenAlex

    Show abstract

    INTRODUCTION: Hypertensive disorders of pregnancy (HDP) affect up to 10% of all pregnancies annually and are associated with an increased risk of maternal and fetal morbidity and mortality. This guideline represents an update of the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines for the management of hypertensive disorders of pregnancy 2014 and has been approved by the National Health and Medical Research Council (NHMRC) under section 14A of the National Health and Medical Research Council Act 1992. In approving the guideline recommendations, NHMRC considers that the guideline meets NHMRC's standard for clinical practice guidelines. MAIN RECOMMENDATIONS: A total of 39 recommendations on screening, preventing, diagnosing and managing HDP, especially preeclampsia, are presented in this guideline. Recommendations are presented as either evidence-based recommendations or practice points. Evidence-based recommendations are presented with the strength of recommendation and quality of evidence. Practice points were generated where there was inadequate…

  6. 6
    top 2.2%

    National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030

    Aletta Elisabeth Schutte, Belinda Bennett, Clara Kayei Chow, Geoffrey C. CLOUD, Kerry Doyle and 23 more

    36 citationsOpen access (CC-BY)doi:10.5694/mja2.52373OpenAlex

    Show abstract

    Background: Raised blood pressure is the leading preventable cause of death in Australia. One in three Australian adults (6.8 million people) have hypertension, defined as clinic or office blood pressure greater than or equal to 140/90mmHg, based on randomised population data.10 Screening campaigns found that about half of these adults (3.4 million) have not had their high blood pressure values detected and are unaware of their hypertension,11 hence are not receiving appropriate treatment. Of those who are diagnosed with hypertension, and treated in the general population, only 32% (2.2 million) are treated effectively, that is, reducing their blood pressure to less than 140/90mmHg (Box 1).10,11 Australians who visit primary care centres have somewhat different rates, where 55% of patients are treated and have their blood pressure effectively controlled.12 Goal: Increase current population blood pressure control rates (<140/90mmHg) from 32% to at least 70% by 2030.5,10 Targets and strategies: The roadmap for 2024–2030 (Box 2) is built on three pillars: (A) prevent; (B) detect; and…

  7. 7
    top 2.5%

    Patient blood management guideline for adults with critical bleeding

    Biswadev Mitra, Margaret Jorgensen, Michael Charles Reade, Anastazia Keegan, Anthony Holley and 5 more

    36 citationsOpen access (CC-BY-NC-ND)doi:10.5694/mja2.52212OpenAlex

    Show abstract

    INTRODUCTION: The management of patients with critical bleeding requires a multidisciplinary approach to achieve haemostasis, optimise physiology, and guide blood component use. The 2011 Patient blood management guidelines: module 1 - critical bleeding/massive transfusion were updated and published. Systematic reviews were conducted for pre-specified research questions, and recommendations were based on meta-analyses of included studies. MAIN RECOMMENDATIONS: The critical bleeding/massive transfusion guideline includes seven recommendations and 11 good practice statements addressing: major haemorrhage protocols (MHPs) facilitating a multidisciplinary approach to haemorrhage control, correction of coagulopathy and normalisation of physiological derangement; measurement of physiological, biochemical and metabolic parameters in critical bleeding/massive transfusion; the optimal ratio of red blood cells to other blood components; the use of tranexamic acid; viscoelastic haemostatic assays; and cell salvage. CHANGES IN MANAGEMENT AS A RESULT OF THE GUIDELINE: The new guideline recommends…

  8. 8
    top 2.9%

    The 2023 report of the MJA –LancetCountdown on health and climate change: sustainability needed in Australia's health care sector

    Paul J. Beggs, Stefan Trueck, Martina K. Linnenluecke, Hilary Bambrick, Anthony Guy Capon and 20 more

    30 citationsOpen access (CC-BY-NC)doi:10.5694/mja2.52245OpenAlex

    Show abstract

    The MJA-Lancet Countdown on health and climate change in Australia was established in 2017 and produced its first national assessment in 2018 and annual updates in 2019, 2020, 2021 and 2022. It examines five broad domains: health hazards, exposures and impacts; adaptation, planning and resilience for health; mitigation actions and health co-benefits; economics and finance; and public and political engagement. In this, the sixth report of the MJA-Lancet Countdown, we track progress on an extensive suite of indicators across these five domains, accessing and presenting the latest data and further refining and developing our analyses. Our results highlight the health and economic costs of inaction on health and climate change. A series of major flood events across the four eastern states of Australia in 2022 was the main contributor to insured losses from climate-related catastrophes of $7.168 billion - the highest amount on record. The floods also directly caused 23 deaths and resulted in the displacement of tens of thousands of people. High red meat and processed meat consumption and…

  9. 9
    top 3.2%

    Changes in the incidence of melanoma in Australia, 2006–2021, by age group and ancestry: a modelling study

    David C. Whiteman, Rachel Ε. Neale, Peter David Baade, Catherine M. Olsen, Nirmala Pandeya

    29 citationsOpen access (CC-BY)doi:10.5694/mja2.52404OpenAlex

    Show abstract

    OBJECTIVES: To estimate the incidence of melanoma in Australia among people with ancestries associated with low, moderate, or high risk of melanoma, by sex and 5-year age group; to establish whether age-specific incidence rates by ancestry risk group have changed over time. STUDY DESIGN: Modelling study; United States (SEER database) melanoma incidence rates for representative ancestral populations and Australian census data (2006, 2011, 2016, 2021) used to estimate Australian melanoma incidence rates by ancestry-based risk. SETTING, PARTICIPANTS: Australia, 2006-2021. MAIN OUTCOME MEASURES: Age-specific invasive melanoma incidence rates, and average annual percentage change (AAPC) in age-specific melanoma rates, by ancestry-based risk group, sex, and 5-year age group. RESULTS: The proportion of people in Australia who reported high risk (European) ancestry declined from 85.3% in 2006 to 71.1% in 2021. The estimated age-standardised melanoma incidence rate was higher for people with high risk ancestry (2021: males, 82.2 [95% confidence interval {CI}, 80.5-83.8] cases per 100 000…

  10. 10
    top 3.6%

    How should artificial intelligence be used in Australian health care? Recommendations from a citizens’ jury

    Stacy M. Carter, Yves Saint James Aquino, Lucy Carolan, Emma Kellie Frost, Chris Degeling and 5 more

    25 citationsOpen access (CC-BY)doi:10.5694/mja2.52283OpenAlex

    Show abstract

    OBJECTIVE: To support a diverse sample of Australians to make recommendations about the use of artificial intelligence (AI) technology in health care. STUDY DESIGN: Citizens' jury, deliberating the question: "Under which circumstances, if any, should artificial intelligence be used in Australian health systems to detect or diagnose disease?" SETTING, PARTICIPANTS: Thirty Australian adults recruited by Sortition Foundation using random invitation and stratified selection to reflect population proportions by gender, age, ancestry, highest level of education, and residential location (state/territory; urban, regional, rural). The jury process took 18 days (16 March - 2 April 2023): fifteen days online and three days face-to-face in Sydney, where the jurors, both in small groups and together, were informed about and discussed the question, and developed recommendations with reasons. Jurors received extensive information: a printed handbook, online documents, and recorded presentations by four expert speakers. Jurors asked questions and received answers from the experts during the online…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to The Medical Journal of Australia with publication year 2024, excluding retracted works and paratext such as editorials and errata. The top 10 by citation count are listed; the percentile is the rank divided by the cohort size. 10 of the 10 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 10 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.